Meningococcal B vaccination: real-world experience and future perspectives

Kuhdari, Parvanè; Stefanati, Armando; Lupi, Silvia; Valente, Nicoletta; Gabutti, Giovanni

doi:10.1080/20477724.2016.1195072

Cited by 20 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise, MenB vaccines can also induce some substantial cross-reactive T cell immunity against SARS-CoV-2. However, MenB vaccines are unlikely responsible for the observed resilient of children to SARS-CoV-2 worldwide; MenB vaccines have been introduced very recently, in the last decade, and not everywhere ( 58 , 59 ). In contrast, combination DTP vaccines are included in every single vaccination program since the 1940–50 ( 50 ).…”

Section: Resultsmentioning

confidence: 99%

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines

Reche

2020

Front. Immunol.

View full text Add to dashboard Cite

The recently emerged SARS-CoV-2 causing the ongoing COVID-19 pandemic is particularly virulent in the elderly while children are largely spared. Here, we explored the potential role of cross-reactive immunity acquired from pediatric vaccinations and exposure to common human pathogens in the protection and pathology of COVID-19. To that end, we sought for peptide matches to SARS-CoV-2 (identity ≥ 80%, in at least eight residues) in the proteomes of 25 human pathogens and in vaccine antigens, and subsequently predicted their T and B cell reactivity to identify potential cross-reactive epitopes. We found that viruses subject to pediatric vaccinations do not contain cross-reactive epitopes with SARS-CoV-2, precluding that they can provide any general protection against COVID-19. Likewise, common viruses including rhinovirus, respiratory syncytial virus, influenza virus, and several herpesviruses are also poor or null sources of cross-reactive immunity to SARS-CoV-2, discarding that immunological memory against these viruses can have any general protective or pathological role in COVID-19. In contrast, we found combination vaccines for treating diphtheria, tetanus, and pertussis infectious diseases (DTP vaccine) to be significant sources of potential cross-reactive immunity to SARS-CoV-2. DTP crossreactive epitopes with SARS-CoV-2 include numerous CD8 and CD4 T cell epitopes with broad population protection coverage and potentially neutralizing B cell epitopes in SARS-CoV-2 Spike protein. Worldwide, children receive several DTP vaccinations, including three-four doses the first year of life and one at 4-6 years of age. Moreover, a low antigenic Tdap dose is also given at ages 9-14. Thereby, children may well be protected from SARS-CoV-2 through cross-reactive immunity elicited by DTP vaccinations, supporting testing in the general population to prevent COVID-19.

show abstract

Section: Resultsmentioning

confidence: 99%

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines

Reche

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The highest IMD incidence rate in children <1 year suggests that the most effective prevention strategy is to focus the immunization intervention on this age group. The impact of this vaccine has been documented in several countries with reliable surveillance systems, and includes a direct decrease in incidence rates, as well as indirect benefits due to the induction of herd protection [41].…”

Section: Discussionmentioning

confidence: 99%

Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0–5 years Old Polish Children

Drozd-Dąbrowska

Topczewska

Korzeń³

et al. 2019

IJERPH

View full text Add to dashboard Cite

In Poland, in addition to mandatory, free of charge vaccines, listed in the national immunization schedule, numerous self-paid vaccinations are recommended, including meningococcal vaccination (MV). To assess MV uptake among ≤5-year-old children and to evaluate parental knowledge and attitudes regarding invasive meningococcal disease (IMD). A cross-sectional study was conducted in 2018 among 350 parents (mean age: 32.3 years), attending three randomly selected primary care clinics in Szczecin region, Poland. Anonymous questionnaires were administered to the parents by researchers, present at the time the survey was conducted, to self-complete on a voluntary basis. Chi-square or Fisher’s exact for categorical and Mann–Whitney U test for continuous variables. Variables significantly (p < 0.05) associated with ‘good knowledge’ in the bivariate analysis were used to build a logistic regression model. It was found that the response rate was 93.4%, and MV uptake among children was 29.5%. The main knowledge sources were medical staff and media; 72.5% had ever received information about IMD. Only 18.8% of parents self-assessed their knowledge regarding IMD as good; 61.8% scored >50% in the knowledge test 58.9% knew the mode of transmission, 58.7% recognized the severity of meningitis, and 79.7% knew that bacterial meningitis is a vaccine-preventive disease. Knowledge regarding IMD was higher among parents with higher educational level (OR = 3.37; p = 0.01), from urban facilities (OR = 2.20; p = 0.02), who received previous information about IMD (OR = 2.85; p = 0.01) and self-assessed their knowledge as good (OR = 2.59; p = 0.04). Low MV coverage among children up to five years old and knowledge gaps about IMD call for awareness campaigns which may increase the coverage. Although educational interventions should cover all parents, those from provincial facilities, representing lower education level need special attention.

show abstract

“…After having been shown to be safe [41] and effective in this age group [42], it is now licensed in several countries, but its recommendation varies greatly. Used in 2013 to manage Men B outbreaks in two US universities, it demonstrated the ability to quickly achieve high immunity rates, curbing the outbreak as no new cases occurred among vaccinees [43]. Thus, the development of meningococcal conjugate vaccines has had a significant impact on the incidence of these rare but severe diseases always requiring ICU admission, in which a more widespread use of Men B vaccines could reduce further.…”

Section: Yellow Fever Neisseria Meningitidis Cholera Ebola: How Vamentioning

confidence: 99%

Missed vaccinations and critical care admission: all you may wish to know or rediscover—a narrative review

et al. 2019

View full text Add to dashboard Cite

Most vaccines are so effective that they could lead to the control/elimination of the diseases they target and directly impact on intensive care admissions or complications. This is best illustrated by the use of vaccines against Haemophilus influenzae type b, Streptococcus pneumoniae, zoster, yellow fever, Ebola virus, influenza or measles-but also by third party strategies such as maternal, toddler and care-giver immunization. However, each of these vaccine-induced protection is threatened by insufficient vaccine uptake. Here, we briefly discuss how vaccine hesitancy has led to the resurgence of diseases that were considered as controlled and explore the effect of vaccine-hesitant healthcare workers on nosocomial infections. As intensive care physicians are in charge of polymorbid patients, we briefly summarize the current recommendations for vaccinations in high-risk patients. We finally give some perspective on ongoing research, and discuss how institutional policies and intensive care physicians could play a role in increasing the impact of vaccination, overall and in intensive care units.

show abstract

Meningococcal B vaccination: real-world experience and future perspectives

Cited by 20 publications

References 38 publications

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines

Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0–5 years Old Polish Children

Missed vaccinations and critical care admission: all you may wish to know or rediscover—a narrative review

Contact Info

Product

Resources

About